 Compugen Ltd NASDAQ: CGEN has announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squibb Cos NYSE: BMS Opdivo nivolumab. Data were presented at the ASCO 2021 Annual Meeting. 